Instrument Inactif

Communiqués BrainsWay Ltd. TEL AVIV STOCK EXCHANGE

Actions

BWAY

IL0011007189

Equipement et technologie médicale avancés

Communiqués

29/07	BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026	AQ
20/07	BrainsWay Announces Strategic Investment in Radial Health, Inc.	AQ
16/07	BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral	AQ
29/06	BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder	AQ
22/06	BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives	AQ
09/06	BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting	AQ
18/05	BrainsWay Announces Minority-Stake Investment in Hopemark Health	AQ
14/05	BrainsWay : Q4 2025	PU
14/05	BrainsWay : May 2026 Investor Deck	PU
13/05	BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights	AQ
29/04	BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026	AQ
15/04	BrainsWay : Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy	PU
13/04	BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference	AQ
26/03	BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD	AQ
19/03	BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health	AQ
18/03	BrainsWay : March 2026 Investor Deck	PU
11/03	BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights	AQ
04/03	Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment	AQ
25/02	BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026	AQ
23/02	BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day	AQ
19/02	BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.	AQ
18/02	BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care	AQ
17/02	BrainsWay Announces Change in ADS-to-Ordinary Share Ratio	AQ
21/01	BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™	AQ
12/01	BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)	AQ